Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
Cervical Dystonia
About this trial
This is an interventional treatment trial for Cervical Dystonia
Eligibility Criteria
Inclusion Criteria: Cervical dystonia with at least 18 months since onset, and previously untreated with botulinum toxin or previously treated with botulinum toxin type A or B with a minimum interval of 16 weeks since the last injection and having returned at least to their usual pre-treatment status TWSTRS severity, disability and total scores meeting the defined criteria at baseline Exclusion Criteria: Pure anterocollis or pure retrocollis In apparent remission from cervical dystonia Previous poor response to the last two botulinum toxin type A or type B treatments Being treated with type B toxin due to lack of efficacy to type A toxin or have known neutralizing antibodies to type A toxin
Sites / Locations
- St. Joseph's Hospital and Medical Center
- Parkinson's and Movement Disorder Institute
- USC School of Medicine
- University of Florida
- University of Miami
- Emory University
- Rush University Medical Center
- University of Iowa
- University of Maryland Medical Center
- Wayne State University Medical Center
- Albany Medical Center
- Beth Israel Medical Center
- Columbia University
- Wake Forest University
- Allegeheny General
- University of Texas Southwest
- Baylor College of Medicine
- Swedish Neuroscience
- Scientific Research Institute of Neurology, RAMS
- Clinic "Cecil Plus"
- Municipal Multi-Speciality Hospital #2
- St Petersburg Pavlov State Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Drug: abobotulinumtoxinA (Dysport®)
Placebo